Active • Host: HEK293 cells • AA: 22-285 • Tag: C-terminal His • MW: 31 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

FGFR1 Extracellular Domain (human, recombinant)

Item No. 33735

Technical Information
Synonyms
  • Basic Fibroblast Growth Factor Receptor 1
  • bFGF-R-1
  • BFGFR
  • CD331
  • Fibroblast Growth Factor Receptor 1
  • FGFBR
  • FLT2
  • Fms-like Tyrosine Kinase 2
Purity
≥98% estimated by SDS-PAGE
Endotoxin Testing
<1.0 EU/µg determined by the LAL endotoxin assay
Source
Active recombinant C-terminal human His-tagged FGFR1 expressed in HEK293 cells
Amino Acids
22-285
MW
31 kDa
Lyophilized from sterile PBS, pH 7.4
UniProt Accession №
P11362
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Fibroblast growth factor receptor 1 (FGFR1) is a growth factor receptor with roles in cell migration, differentiation, and survival, as well as apoptosis, chemotaxis, and embryonic development.1,2 It is composed of an N-terminal extracellular domain, which contains three immunoglobulin-like (Ig-like) domains, including the FGF ligand-binding domain, an acidic box, and a CAM-homology domain, a transmembrane domain, and a C-terminal tyrosine kinase domain. FGFR1 is expressed throughout the pre-differentiated mesenchyme of the cranium, in midfacial mesenchyme, and the endochondral skull base during early embryonic development, and broadly expressed in epithelial, osteogenic, and chondrogenic cell lineages by 10 to 13 weeks gestation.3 Upon ligand binding, FGFR1 dimerizes, resulting in autophosphorylation of the tyrosine kinase domain and activation of various intracellular signaling pathways, including the ERK/MAPK pathway.1 Mutations in FGFR1 induce various craniofacial dysostosis syndromes, such as Crouzon, Pfeiffer, and Jackson-Weiss syndromes that feature basicranial and midfacial deformities.3 FGFR1 amplifications, translocations, and fusions are associated with lung cancer, 8p11 myeloproliferative syndrome, and glioblastoma multiforme, respectively.4 Cayman’s FGFR1 Extracellular Domain (human, recombinant) can be used for enzyme activity assays. This protein consists of 275 amino acids, has a calculated molecular weight of 31 kDa, and a predicted N-terminus of Arg22 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 50-55 kDa due to glycosylation.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Böttcher, R.T., and Niehrs, C. Fibroblast growth factor signaling during early vertebrate development. Endocr. Rev. 26(1), 63-77 (2005).

    2. Villanueva, C., and de Roux, N. FGFR1 mutations in Kallmann syndrome. Front. Horm. Res. 39, 51-61 (2010).

    3. Britto, J.A., Evans, R.D., Hayward, R.D., et alFrom genotype to phenotype: The differential expression of FGF, FGFR, and TGFβ genes characterizes human cranioskeletal development and reflects clinical presentation in FGFR syndromes. Plast. Reconstr. Surg. 108(7), 2026-2039 (2001).

    4. Katoh, M., and Nakagama, H. FGF receptors: Cancer biology and therapeutics. Med. Res. Rev. 34(2), 280-300 (2014).